Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995 Dec;34(12):1672-81.
Greenspan, S I. & Wieder, S. Developmental patterns and outcomes in infants and children with disorders in relating and communicating A chart review of 200 cases of children with autistic spectrum diagnoses. J Dev Learning Disord, 1997;1:87-141.
Martin A, Scahill L, Klin A, Volkmar FR Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):923-31.
Rutter M The development of infantile autism. Psychol Med. 1974 May;4(2):147-63. Review.
Steffenburg S Neuropsychiatric assessment of children with autism: a population-based study. Dev Med Child Neurol. 1991 Jun;33(6):495-511.
Thal DJ, O'Hanlon L, Clemmons M, Fralin L Validity of a parent report measure of vocabulary and syntax for preschool children with language impairment. J Speech Lang Hear Res. 1999 Apr;42(2):482-96.
Woodruff-Pak DS, Vogel RW 3rd, Wenk GL Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
